PMID: 9662754Jul 15, 1998Paper

Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention

Seminars in Arthritis and Rheumatism
G Nesher, R Ruchlemer

Abstract

The therapeutic applications of alpha-interferon (IFN) have expanded greatly to include chronic viral hepatitis and malignant disorders. Autoimmune phenomena occur frequently with IFN therapy, but arthritis is uncommon. We describe the clinical features and treatment of IFN-induced arthritis. A patient with chronic myelogenous leukemia who developed arthritis secondary to IFN therapy is presented. The clinical features and treatment of this condition in 37 additional cases are reviewed. The most common clinical presentation was symmetric polyarthritis. This was associated with antinuclear antibodies in 72% of patients and rheumatoid factor in 34%. Cessation of IFN, with or without the addition of antiinflammatory or remittive agents, resulted in remission of arthritis in 89% and 71% of the cases, respectively. Restarting IFN therapy resulted in recurrence of arthritis in 63%. In the patient described in this report, recurrence of arthritis was prevented by coadministration of hydroxychloroquine (HCQ) and prednisone. Arthritis is an uncommon complication of IFN therapy; but it may lead to cessation of this treatment modality. In such cases, coadministration of a remittive agent such as HCQ may enable reinstitution of IFN therapy...Continue Reading

References

Oct 1, 1992·Clinical Immunology and Immunopathology·U B WandlN Niederle
Aug 1, 1992·Annals of Internal Medicine·Y Ueno, T Sohma
Mar 1, 1992·Annals of Internal Medicine·P ChazerainM F Kahn
Jun 1, 1988·The American Journal of the Medical Sciences·A Schattner
Aug 1, 1988·Clinical Immunology and Immunopathology·P J HertzogA W Linnane
Aug 1, 1986·Annals of Internal Medicine·L P AkardJ H Saiers
Oct 21, 1982·The New England Journal of Medicine·S BorgströmH O Sjögren
Sep 1, 1993·Clinical Rheumatology·L D'HondtC Docquier
Feb 1, 1995·Neurology·A P BatocchiP Tonali
Mar 1, 1995·The Journal of Clinical Endocrinology and Metabolism·A ImagawaY Matsuzawa
Sep 1, 1996·Journal of Hepatology·T OkanoueK Kashima

❮ Previous
Next ❯

Citations

Feb 27, 2004·Autoimmunity·Carmen Gota, Leonard Calabrese
Feb 3, 2006·International Journal of Clinical Practice·S Alazemi, M A Campos
Mar 24, 2016·Rheumatology International·Marwan H Adwan
Sep 1, 1999·Rheumatic Diseases Clinics of North America·D VassilopoulosR M Strauss
Sep 13, 2015·Best Practice & Research. Clinical Rheumatology·Worawit Louthrenoo
Mar 20, 2010·Autoimmunity·Martina BiggioggeroPier Luigi Meroni
Dec 30, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Bernard Bannwarth
Aug 22, 2000·Rheumatology·G Kallarackal, S M Jones
Dec 5, 2006·Current Opinion in Rheumatology·Frances A Y Borg, David A Isenberg
Jan 23, 1999·Current Opinion in Rheumatology·M EhrenfeldY Shoenfeld
Jan 27, 2000·Current Opinion in Rheumatology·R A Watts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.